Neurogene (NGNE) Tax Provisions (2013 - 2014)
Neurogene's (NGNE) quarterly Tax Provisions came in at $185222.0 in Q4 2014, up 420859.09% YoY from N/an in Q4 2013, and up 83533.33% on a QoQ basis from -$222.0 in Q3 2014.
Neurogene (NGNE) Tax Provisions (2013 - 2014) Analysis & Trends
Neurogene (NGNE) has 2 years of Tax Provisions data on file, last reported at $185222.0 in Q4 2014.
- Quarterly Tax Provisions rose 420859.09% year-over-year to $185222.0 in Q4 2014, while the trailing twelve-month figure through Dec 2014 was $180000.0 (changed N/A YoY) and the FY2015 annual result came in at $446000.0, up 141.08% from the prior year.
- Tax Provisions grew to $185222.0 in Q4 2014, from -$222.0 in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $185222.0 in Q4 2014 to a low of -$5044.0 in Q3 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 185,222.00 |
| Sep 30, 2014 | -222.00 |
| Dec 31, 2013 | 44.00 |
| Sep 30, 2013 | -5,044.00 |